NEW YORK (GenomeWeb News) – Pharmacogenetic testing firm PGXL Laboratories announced on Thursday a long-term national distribution deal with Essential Molecular Testing for PGXL's drug sensitivity testing.

The partnership, called PGXL Partners, provides the Louisville, Ky.-based laboratory a larger sales force to address growing demand for its tests. In a statement, PGXL Labs President Roland Valdes Jr., said that the company has increased sales of its tests to thousands each month from hundreds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.